Skip to content

A clinical trial for comparing the breast conservation and breast conservation conbined with immediate reconstruction

A clinical trial for comparing the breast conservation and breast conservation conbined with immediate reconstruction

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIC-16009685
Enrollment
Unknown
Registered
2016-10-28
Start date
2016-10-30
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Group 1:breast conservation combined with breast reconstruction operation
Group 2:breast conservation operation

Sponsors

The affiliated Ninth Poeple's Hospital, Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) aged 20 to 60 years old; (2) patients with confirmed breast willingness; (3) of the hollow needle biopsy, histopathologic diagnosis of invasive breast cancer; (4) in patients with normal liver and kidney function, blood routine; (5) receied radiation and chemotherapy, chemotherapy regimens for CEF or EC - T. (6) signed informed consent, and willing to cooperate to neoadjuvant therapy and postoperative treatment and follow-up, good adherence.

Exclusion criteria

Exclusion criteria: (1) have diabetes, hyperlipidemia, severe cardio-cerebrovascular disease, kidney disease patients. (2) do not accept our MDT provide postoperative chemoradiotherapy solution; (3). In addition to having breast surgery, issue of breast shape and postoperative rehabilitation, also accept other treatment; (4) breast cancer patients with distant metastases and proven; (5) patients with a history of other malignant tumor; (6) known for any drugs in the neoadjuvant therapy has a history of severe allergic; (7) and breast cancer during pregnancy and lactation Male breast cancer patients (8); (9) have poor patient compliance.

Design outcomes

Primary

MeasureTime frame
recurrent rate;

Secondary

MeasureTime frame
metastasis rate;

Countries

China

Contacts

Public ContactShanyu Guo

The affiliated ninth poeple's hospital, Shanghai Jiaotong University

guoshyu@sina.com+86 13621968889

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026